·SEC EDGARLow
JOBSON CHARLES E purchased $19K of JYNT
JOBSON CHARLES E purchased 2,825 shares of JOINT Corp (JYNT) at $6.65 on 2026-11-10.
StockNASDAQ · US · USDHealthcare · Medical Care Facilities
$JYNT
JOINT Corp
The Joint is a franchisor and operator of chiropractic clinics serving patients through a private-pay, cash-based model that does not accept insurance or provide Medicare-covered services. Its clinics offer appointment-free chiropractic adjustments in open-bay settings, along with membership and wellness treatment plans and packages. The Joint makes money from franchise royalties of 7.0% of gross sales, a national marketing fee of 2.0% of franchised clinic sales, and initial franchise fees. It also operates company-owned or managed clinics while shifting toward a franchisor-focused business. As of December 31, 2025, The Joint has 960 clinics operating in 43 states, including 885 owned or managed by franchisees and 75 owned or managed by the company. Its clinics employ licensed chiropractors and focus on non-acute care. The company is headquartered in Scottsdale, Arizona.
Price · $JYNTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $JYNT in the last 7 days.
Insider · 30dAll trades →
- Buys
- $1.6M 3 txs
- Sells
- — 0 txs
JOBSON CHARLES E3× · $1.6M
10b5-1 share of filings0%
Top stories · $JYNTMore →
·SEC EDGAR
JOBSON CHARLES E purchased $1.6M of JYNT
JOBSON CHARLES E purchased 236,116 shares of JOINT Corp (JYNT) at $6.65 ($1.57M total) on 2026-11-09.
·SEC EDGAR
JOBSON CHARLES E purchased $1K of JYNT
JOBSON CHARLES E purchased 179 shares of JOINT Corp (JYNT) at $6.65 on 2026-11-06.
JYNT sentiment & insider activity
Recent JYNT coverage spans earnings, insider activity and financial news.
In the last 30 days, JYNT insiders filed 3 SEC Form 4 transactions — 3 purchases ($1.6M) and no sales. The most active reporter was JOBSON CHARLES E with 3 filings.
What's driving JYNT
Small insider purchase likely has minimal immediate price impact.
Insider buying suggests confidence and may support short-term price appreciation.
Small insider purchase likely has minimal immediate price impact.
Guidance provides a fresh data point for valuation models.
Guidance cut and modest revenue growth suggest near-term downside pressure.
AlphAI scores every news story that mentions JYNT with an AI model for sentiment and relevance, and aggregates insider trades from JOINT Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $JYNT
Score
JOBSON CHARLES E purchased $19K of JYNT
JOBSON CHARLES E purchased 2,825 shares of JOINT Corp (JYNT) at $6.65 on 2026-11-10.
JOBSON CHARLES E purchased $1.6M of JYNT
JOBSON CHARLES E purchased 236,116 shares of JOINT Corp (JYNT) at $6.65 ($1.57M total) on 2026-11-09.
JOBSON CHARLES E purchased $1K of JYNT
JOBSON CHARLES E purchased 179 shares of JOINT Corp (JYNT) at $6.65 on 2026-11-06.
The Joint expects $508M-$512M in 2026 system-wide sales while targeting comp sales turnaround (NASDAQ:JYNT)
The Joint Corp. (JYNT) anticipates system-wide sales of $508M-$512M in 2026, aiming for a turnaround in comparable sales. This outlook was shared during the company's Q3 2026 earnings call.
The Joint Corp (JYNT) (Q3 2026) Earnings Call Highlights: Refranchising Pays Off
The Joint Corp (JYNT) reported Q3 2026 revenue of $13.6M, up 1%, with system-wide sales down 3.1%. Net income rose to $1.5M, and adjusted EBITDA increased to $2.3M. CEO Sanjeev Rajdhan noted refranchising is nearly complete, with 50 fewer clinics expected by year-end. The company reacquired Texas regional developer rights for $8M. Guidance was adjusted to reflect lower system-wide sales.
The Joint Corp. Reports Third Quarter 2026 Financial Results
JOINT Corp (JYNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 The Joint Corp. Reports Third Quarter 2026 Financial Results - Revenue Increases to $13.6 Million - - Net Income from Continuing Operations Increases by $1.2 Million to $1.5 Million and Adjusted EBITDA From Continuing Operations Increases by $0.9 Million to $2.3 Mill
The Joint Chiropractic Expands Growth Opportunities Through Strategic Territory Reacquisition
The Joint Corp. (JYNT) reacquired regional developer rights in Texas, adding to a series of 2026 territory reacquisitions. These moves represent over 150 potential new clinics, advancing the company's shift to a pure-play franchisor model. The strategy aims to strengthen franchisee support and expand the brand's footprint.
The Joint Reacquires Texas Development Rights for $8 Million Cash Plus Up to $2 Million Earnout
JOINT Corp reacquired Texas regional development rights for $8.0M in cash, with up to $2.0M in earnouts tied to sales. The deal, effective October 1, 2026, includes 141 franchised clinics and aims to simplify royalties and enhance market control. The company terminated existing Texas regional developer agreements mutually.
JOINT Corp (JYNT): Entry into a Material Definitive Agreement
JOINT Corp (JYNT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On October 1, 2026, we entered into an Asset Purchase Agreement (the “APA”) with The Joint Franchises San Antonio, LLC, a Texas limited liability company, The Joint Franchises DFW, LLC, a Texas limited liability company, The
The Joint Corp. Reports Second Quarter 2026 Financial Results
JOINT Corp (JYNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 The Joint Corp. Reports Second Quarter 2026 Financial Results - Consolidated Net Income Increases $560,000 to $653,000; Adjusted EBITDA From Continuing Operations Increases by $1.4 Million - - Cash Flow from Operating Activities Rises 152% to $2.2 Million, Driving Fr